Pegvisomant - Biologic Drug Details

Summary for pegvisomant

Tradenames:	1
High Confidence Patents:	1
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for pegvisomant
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for pegvisomant

Recent Clinical Trials for pegvisomant

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 3
St. Michael's Hospital, Toronto	Phase 3

See all pegvisomant clinical trials

Recent Litigation for pegvisomant

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
Supernus Pharmaceuticals, Inc v. Actavis Inc.	2016-02-23

See all pegvisomant litigation

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pegvisomant Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pegvisomant Derived from Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Pharmacia & Upjohn Company Llc	SOMAVERT	pegvisomant	For Injection	021106		2015-09-21	Company disclosures

3) Low Certainty: US Patents for pegvisomant Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Pharmacia & Upjohn Company Llc	SOMAVERT	pegvisomant	For Injection	021106		2032-02-15	Patent claims search
Pharmacia & Upjohn Company Llc	SOMAVERT	pegvisomant	For Injection	021106		2026-06-08	Patent claims search
Pharmacia & Upjohn Company Llc	SOMAVERT	pegvisomant	For Injection	021106		2024-12-29	Patent claims search
Pharmacia & Upjohn Company Llc	SOMAVERT	pegvisomant	For Injection	021106		2032-07-03	Patent claims search
Pharmacia & Upjohn Company Llc	SOMAVERT	pegvisomant	For Injection	021106		2029-01-29	Patent claims search
Pharmacia & Upjohn Company Llc	SOMAVERT	pegvisomant	For Injection	021106		2040-11-06	Patent claims search

International Patents for pegvisomant

Country	Patent Number	Estimated Expiration
Japan	2005021157
Australia	718439
Hong Kong	1012508
Japan	3267293
European Patent Office	0851925
Austria	E189526

Supplementary Protection Certificates for pegvisomant

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C00851925/01	Switzerland		FORMER REPRESENTATIVE: BOVARD AG PATENTANWAELTE, CH
SPC/GB05/047	United Kingdom		PRODUCT NAME: PEGVISOMANT, OPTIONALLY IN THE FORM OF A PEGYLATION VARIANT; REGISTERED: UK EU/1/02/240/001 20021115; UK EU/1/02/240/002 20021115; UK EU/1/02/240/003 20021115
122006000003	Germany		PRODUCT NAME: WIRKSTOFFZUSAMMENSETZUNG UMFASSEND PEGVISOMANT; REGISTRATION NO/DATE: EU/1/02/240/001-003 20021113
SPC029/2005	Ireland		SPC029/2005: 20061023, EXPIRES: 20171112
132006901381900	Italy		AUTHORISATION NUMBER(S) AND DATE(S): EU/1/02/240/001-003, 20021113
2005C/037	Belgium		PRODUCT NAME: PEGVISOMANT; AUTHORISATION NUMBER AND DATE: EU/1/02/240/001 20021115